|
WO2020097127A2
|
|
B-cell activating cd73 antibodies
|
|
WO2020068583A1
|
|
Processes for making triazolo [4,5d] pyramidine derivatives and intermediates thereof
|
|
EP3616753A1
|
|
Compounds for modulating adenosine a2b receptor and adenosine a2a receptor
|
|
CA3106038A1
|
|
Methods for detecting and treating cancers having adenosine pathway activation
|
|
WO2020014666A1
|
|
Methods for detecting and treating cancers having adenosine pathway activation
|
|
US2019231783A1
|
|
Pharmaceutical formulations
|
|
KR20200117998A
|
|
Pharmaceutical composition
|
|
EP3706752A1
|
|
Combination therapy for cancer treatment
|
|
CN111565722A
|
|
Adenosine pathway inhibitors for cancer treatment
|
|
CN111629728A
|
|
Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor
|
|
EP3606962A1
|
|
Methods for treating cd73hi tumors
|
|
US2019022096A1
|
|
Methods of treating cancer
|
|
US2020297728A1
|
|
Methods of treating cancer
|
|
EP3600292A1
|
|
Processes for making triazolo[4,5d]pyramidine derivatives and intermediates thereof
|
|
AU2017358901A1
|
|
Compounds and methods for modulating interleukin-2-inducible T-cell kinase
|
|
US2018009899A1
|
|
Anti-CD73 antibodies
|
|
KR20180133415A
|
|
Compounds and Methods for the Control of Bruton Type Tyrosine Kinases
|
|
CN108883107A
|
|
The method for the treatment of cancer
|
|
WO2017100670A1
|
|
Humanized anti-cd73 antibodies
|
